Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria - Slideshow (NASDAQ:CUE) 2026-09-24
Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript
Reported Sunday, Cue Biopharma's CUE-221 Shows 60% Complete Hives Resolution Twelve Weeks Off Treatment At 4 Mg/Kg In Phase 2 Chronic Spontaneous Urticaria Study Versus 24% For Omalizumab In Post Hoc Analysis
B. Riley Securities Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $83